Jia Ruan

Dr. Ruan is a Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York Presbyterian Hospital. She specializes in the treatment of lymphoma, and leads clinical research trials in mantle cell lymphoma and peripheral T-cell lymphoma at Weill Cornell Medicine. Dr. Ruan received comprehensive training in medicine and immunology leading to combined MD-PhD degrees from the Tri-Institutional Medical Scientist Training Program of Cornell University, the Rockefeller University and Sloan-Kettering Cancer Institute. She completed residency and fellowship in hematology/oncology at the Stanford University Medical Center and New York Presbyterian Hospital before joining faculty at Weill Cornell Medicine. Dr. Ruan’s research expertise focuses on novel therapeutics targeting tumor microenvironment and tumor immunology in both B-cell and T-cell non-Hodgkin lymphomas. She contributes to the American Society of Hematology as an annual meeting abstract reviewer/coordinating reviewer, Highlights of ASH speaker and Education Session Chair. She has been a faculty for the ASH Clinical Research Training Institute since 2021. She serves on the lymphoma committee of the cooperative intergroup ALLIANCE, and the Lymphoma Research Foundation MCL Research Consortium. She also co-leads the T-cell lymphoma Working Group for the LEO Consortium. Her research efforts were recognized and supported by funding from the LRF, the ASCO Foundation, the LLS, and the NIH. Dr. Ruan has published articles in leading research journals including the Journal of Experimental Medicine, PNAS, Blood, Annals of Oncology, Cancer, the Journal of Clinical Oncology, Lancet Oncology and the New England Journal of Medicine.

Dr. Sarah Rutherford is an Associate Professor of Medicine (Clinical) in the Division of Hematology/Oncology at NYU Langone Health. She is a graduate of the University of Virginia School of Medicine. She completed Internship and Residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia and Fellowship in Hematology/Oncology at New York-Presbyterian Hospital/Weill Cornell Medical College.

Dr. Rutherford has clinical expertise in lymphoma. Her research focuses on novel therapeutic strategies in B-cell and Hodgkin lymphomas. She has received honors from Weill Cornell Medical College and the American Society of Hematology, and support from the New York State Empire Clinical Research Investigator Program, the Lymphoma Research Foundation, the National Institutes of Health Clinical Loan Repayment Program, and the Alliance for Clinical Trials Foundation. She has experience in caring for patients with a variety of lymphomas and hematologic disorders including Hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and peripheral T-cell lymphoma.

I am a Professor in the Division of Hematology and Medical Oncology in the NYU Perlmutter Cancer Center (PCC) at NYU Langone Health, the Clinical Director of Lymphoma and the Translational Director of Hematology. My scientific research focuses on the relationship between systemic immunity, tumor microenvironment, and lymphoid malignancies. I lead a multi-center investigation into the role of the microbiome in aggressive lymphoma and the development of novel CAR T cell constructs , and collaborate in team science with basic scientists in the development of novel immune based therapies, and biomarkers of lymphoma response. I have been among the pioneers of integration of checkpoint inhibitor therapy into the management of Hodgkin lymphoma (HL) developing and led a national ETCTN supported clinical trial in this space. I have also played a key role in the development of novel immune related biomarkers in HL, and serve on national committees leading efforts to improve the next generation of HL therapies. I have contributed to the development of antibody drug conjugates (ADC) and bispecific antibodies in DLBCL and FL , and led national and international studies for relapsed FL and DLBCL. I have successfully obtained external peer-reviewed funding for my translational research from: the Lymphoma Research Foundation, the American Cancer Society, the Leukemia Lymphoma Foundation (LLS) and the National Cancer institute (NCI).

Dr. Alison Moskowitz is an Associate Attending within the Lymphoma service at Memorial Sloan Kettering Cancer Center. She earned her medical degree at Albert Einstein College of Medicine, completed an internship and residency in internal medicine at Columbia University Medical Center, and completed fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.
Dr. Moskowitz’s research is dedicated to developing new treatment strategies for T-cell lymphoma and relapsed/refractory Hodgkin lymphoma. Her research program in Hodgkin lymphoma focuses on developing novel treatment approaches for patients with relapsed or refractory disease and identifying factors predictive of response to therapy and overall outcomes. The aim of this work is to ultimately develop individualized therapy for patients with Hodgkin lymphoma that optimizes cure and limits long-term toxicity.
For T-cell lymphoma, she aims to develop new agents through clinical trials that incorporate strong correlative studies aimed at identifying markers of sensitivity and resistance. These studies will allow us to design personalized treatment approaches, predict optimal combination strategies, and ultimately improve prognosis by rationally designing regimens that target the diverse T-cell lymphoma entities.

Dr. Ruan is a Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York Presbyterian Hospital. She specializes in the treatment of lymphoma, and leads clinical research trials in mantle cell lymphoma and peripheral T-cell lymphoma at Weill Cornell Medicine. Dr. Ruan received comprehensive training in medicine and immunology leading to combined MD-PhD degrees from the Tri-Institutional Medical Scientist Training Program of Cornell University, the Rockefeller University and Sloan-Kettering Cancer Institute. She completed residency and fellowship in hematology/oncology at the Stanford University Medical Center and New York Presbyterian Hospital before joining faculty at Weill Cornell Medicine. Dr. Ruan’s research expertise focuses on novel therapeutics targeting tumor microenvironment and tumor immunology in both B-cell and T-cell non-Hodgkin lymphomas. She contributes to the American Society of Hematology as an annual meeting abstract reviewer/coordinating reviewer, Highlights of ASH speaker and Education Session Chair. She has been a faculty for the ASH Clinical Research Training Institute since 2021. She serves on the lymphoma committee of the cooperative intergroup ALLIANCE, and the Lymphoma Research Foundation MCL Research Consortium. She also co-leads the T-cell lymphoma Working Group for the LEO Consortium. Her research efforts were recognized and supported by funding from the LRF, the ASCO Foundation, the LLS, and the NIH. Dr. Ruan has published articles in leading research journals including the Journal of Experimental Medicine, PNAS, Blood, Annals of Oncology, Cancer, the Journal of Clinical Oncology, Lancet Oncology and the New England Journal of Medicine.